Cite
HARVARD Citation
Sued, O. et al. (n.d.). Dual therapy (ritonavir boosted atazanavir + raltegravir) versus standard triple therapy (ritonavir boosted atazanavir + tenofovir/emtricitabine) in patients failing first line therapy: 48 week results from a randomized pilot study. International journal of infectious diseases. pp. 23-. [Online].